Nanoparticle-based vaccine delivery is a cutting-edge approach that uses nanoparticles to enhance the delivery and effectiveness of vaccines. Nanoparticles are tiny particles that can be engineered to carry and release antigens in a controlled manner, improving the immune system's ability to recognize and respond to pathogens. By encapsulating antigens in nanoparticles, vaccines can be delivered more efficiently to the target cells, ensuring a stronger and more sustained immune response. Nanoparticles can also be designed to mimic the structure of viruses, helping to trigger a more robust immune response while minimizing the risk of side effects. This technology allows for precise control over how the immune system is activated, making it possible to design vaccines that are both more effective and safer. Nanoparticle-based delivery systems have been used in vaccines for cancer, influenza, and other infectious diseases, paving the way for next-generation vaccines.
Khursheed Anwer
IMUNON, United States
Ping Xie
Rutgers University, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Lara Isis Teodoro
Mayo Clinic, United States
Ahmed Abdulazeez
BHRUT Trust, United Kingdom
Elena Chiappini
University of Florence, Italy
Ayesha Zahid
Griffith University, Australia
Livia Daflon Silva
Federal University of State of Rio de Janeiro, Brazil
Neha Bhandari
Chitkara University, IndiaSubmit your abstract Today
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom